Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

ef="http://www.orexigen.com">www.orexigen.com.

Forward-Looking Statements Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding substantially lower cash expenditures for the second half of 2011 and increased expenditures in 2012, the protocol for, and the timing and feasibility of, the CVOT, the initiation of enrollment for the CVOT in the first half of 2012 and the engagement of a clinical research organization, a clear and feasible path forward for Contrave, and the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to come to an agreement with the FDA on the protocol for the CVOT, Orexigen's ability to initiate and conduct the CVOT and the progress and timing thereof, Orexigen's ability to demonstrate in the CVOT that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the CVOT; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resu
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 Research and ... Particle Size Analysis Market 2014-2018" report to their offering. ... Particle size analysis is a technique used to determine the ... or liquid. It is crucial to analyze the size of ... Therefore, particle size analysis is performed to determine the behavior ...
(Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
(Date:7/25/2014)... by researchers from the University of Leicester has ... unlocking the potential to create new materials using ... been published in the prestigious academic journal ... technique to examine in rich detail the structure ... containing an acetylene molecule and a single helium ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3
... , , ... Tobira Therapeutics Inc., a clinical stage biotechnology company committed ... life-threatening and life-altering infectious diseases, today announced pharmacokinetic data ... of TBR-652 in sixty healthy volunteers. TBR-652, a ...
... CAMBRIDGE, Mass., Sept. 14 Ironwood Pharmaceuticals, Inc. today ... officer and senior vice president of marketing and sales. Mr. McCourt ... lead Ironwood,s growing marketing and sales team. , , ... , Mr. McCourt comes to Ironwood from Amgen, where ...
... , , , JOHNSON CITY, ... Rx100, a potent radioprotectant as well as radiomitigator, protects against lethal, ... after exposure. , , In recent experiments, ... subcutaneous dose at either 48 or 72 hours after lethal, whole-body ...
Cached Biology Technology:Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales 2Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation! 2
(Date:7/28/2014)... 28, 2014)The Brain & Behavior Research Foundation today ... Freedman Prizes, recognizing exceptional clinical and basic research ... NARSAD Young Investigator Grants. The grants enable early ... and psychosocial research for the prevention, early detection, ... one in four people. , Six young scientistswinners ...
(Date:7/28/2014)... Inspired Engineering at Harvard University today announced that ... a newly formed private company to accelerate development ... The announcement follows a worldwide license ... and the start-up Emulate Inc., relating to the ... , "This is a big win towards ...
(Date:7/27/2014)... one of the largest prevalence studies to date, researchers ... prevalence estimates for the hepatitis C virus (HCV). Findings ... for the Study of Liver Diseases, indicate that genotype ... million patients infected of which one-third reside in East ... is the next most prevalent, followed by genotypes 2, ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Hepatitis C virus genotype 1 is most prevalent worldwide 2
... Ind. - As the United Nations climate negotiations proceed ... toward quantifying the "socioclimatic" exposure of different countries to ... University and the Abdus Salam International Centre for Theoretical ... the United States - major greenhouse gas-emitting nations that ...
... $50 billion in manufactured goods last year, according to ... $2.6 trillion. By 2011, over $15 billion in nano-enabled ... $3 billion in 2006. And industry experts project that ... consumer food products by 2010. Yet, ...
... from the Early Jurassic has been discovered in Antarctica. ... hammeri and lived about 190 million years ago. , ... based on partial foot, leg and ankle bones found ... at an elevation of more than 13,000 feet. , ...
Cached Biology News:Scientists develop new measure of 'socioclimactic' risk 2Scientists develop new measure of 'socioclimactic' risk 3Scientists develop new measure of 'socioclimactic' risk 4FDLI, PEN co-sponsor major conference on nanotechnology 2FDLI, PEN co-sponsor major conference on nanotechnology 3Massive dinosaur discovered in Antarctica sheds light on life, distribution of sauropodomorphs 2
...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
...
Biology Products: